尽管收入丰厚,指导积极,但Theralase股份下跌了4.6%。 Theralase shares fell 4.6% despite strong earnings and positive guidance.

星期五,Theralarase Technology(CVE:TLT)股份下跌了4.6%,以0.31科多巴元关闭,交易量比平均数高出10%。 Theralase Technologies (CVE:TLT) shares dropped 4.6% to close at C$0.31 on Friday, with trading volume up 10% above average. 加拿大临床阶段公司开发了针对癌症和感染的轻活化疗法和针对肌肉骨骼疼痛的激光技术,报告季度收入丰厚,并更新了2026年指南,然而,尽管P/E比率为负值,库存波动低,投资者对是否购买或出售仍然意见不一。 The Canadian clinical-stage company, developing light-activated therapies for cancer and infections and laser technology for musculoskeletal pain, reported strong quarterly earnings and updated 2026 guidance, yet investor sentiment remains divided on whether to buy or sell despite a negative P/E ratio and low stock volatility.